Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells
文献类型：期刊论文
| 作者 | Lu, Qiu-kai1,2; Fan, Chen1; Xiang, Cai-gui1,2; Wu, Bing1,2; Lu, Hui-min1,2; Feng, Chun-lan1; Yang, Xiao-qian1; Li, Heng1; Tang, Wei1,2
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2021-04-13 |
| 页码 | 11 |
| ISSN号 | 1671-4083 |
| 关键词 | PDE4 apremilast skin fibrosis macrophages |
| DOI | 10.1038/s41401-021-00656-x |
| 通讯作者 | Li, Heng(liheng@simm.ac.cn) ; Tang, Wei(tangwei@simm.ac.cn) |
| 英文摘要 | Systemic sclerosis (SSc) is a life-threatening chronic connective tissue disease with the characteristics of skin fibrosis, vascular injury, and inflammatory infiltrations. Though inhibition of phosphodiesterase 4 (PDE4) has been turned out to be an effective strategy in suppressing inflammation through promoting the accumulation of intracellular cyclic adenosine monophosphate (cAMP), little is known about the functional modes of inhibiting PDE4 by apremilast on the process of SSc. The present research aimed to investigate the therapeutic effects and underlying mechanism of apremilast on SSc. Herein, we found that apremilast could markedly ameliorate the pathological manifestations of SSc, including skin dermal thickness, deposition of collagens, and increased expression of alpha-SMA. Further study demonstrated that apremilast suppressed the recruitment and activation of macrophages and T cells, along with the secretion of inflammatory cytokines, which accounted for the effects of apremilast on modulating the pro-fibrotic processes. Interestingly, apremilast could dose-dependently inhibit the activation of M1 and T cells in vitro through promoting the phosphorylation of CREB. In summary, our research suggested that inhibiting PDE4 by apremilast might provide a novel therapeutic option for clinical treatment of SSc patients. |
| 资助项目 | National Science & Technology Major Project Key New Drug Creation and Manufacturing Program, China[2018ZX09711002-006-011] ; CAS Key Laboratory of Receptor Research[SIMM1904YKF-01] ; Science & Technology Commission of Shanghai Municipality, China[18431907100] ; Personalized Medicines-Molecular Signature-based Drug Discovery and Development, Strategic Priority Research Program of the Chinese Academy of Sciences[XDA12020231] |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | NATURE PUBLISHING GROUP |
| WOS记录号 | WOS:000639768200006 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/296476]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Li, Heng; Tang, Wei |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Lab Antiinflammat & Immunopharmacol, Shanghai 201203, Peoples R China 2.Univ Chinese Acad Sci, Sch Pharm, Beijing 100049, Peoples R China |
| 推荐引用方式 GB/T 7714 | Lu, Qiu-kai,Fan, Chen,Xiang, Cai-gui,et al. Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells[J]. ACTA PHARMACOLOGICA SINICA,2021:11. |
| APA | Lu, Qiu-kai.,Fan, Chen.,Xiang, Cai-gui.,Wu, Bing.,Lu, Hui-min.,...&Tang, Wei.(2021).Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells.ACTA PHARMACOLOGICA SINICA,11. |
| MLA | Lu, Qiu-kai,et al."Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells".ACTA PHARMACOLOGICA SINICA (2021):11. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。